Quantcast

Latest Antiandrogens Stories

2009-06-02 08:23:00

-- Findings Presented at American Society of Clinical Oncology 2009 Annual Meeting and Included in Best of ASCO(R) Educational Program -- SAN FRANCISCO, June 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the presentation of new clinical results from a Phase 1-2 trial evaluating MDV3100, a next-generation androgen receptor antagonist, in castration-resistant prostate cancer (CRPC) patients. The new findings, which include data from all 140 enrolled patients,...

2009-05-21 18:06:00

Access to Late-Stage, First-in-Class Prostate Cancer Treatment Strengthens Presence in Oncology NEW BRUNSWICK, N.J., and LOS ANGELES, May 21 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) and Cougar Biotechnology, Inc. (Nasdaq: CGRB), a development stage biopharmaceutical company with a specific focus on oncology, today announced a definitive agreement whereby Cougar Biotechnology will be acquired for approximately $1.0 billion in a cash tender offer. Cougar Biotechnology,...

2009-04-10 15:36:38

A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs. Chemists and biologists at UCLA and colleagues at several other institutions, including Memorial Sloan-Kettering Cancer Center, have created a new drug to treat a particularly lethal form of the disease, known as castration-resistant prostate cancer, or CRPC. Also referred to as hormone-refractory prostate cancer, CRPC is...

2009-04-07 15:00:00

- Seminal Research on Prostate Cancer Resistance Leads to Development of MDV3100, Novel Drug Candidate - SAN FRANCISCO, April 7 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced publication of an article in the April 9, 2009, issue of Science Express, the online version of the journal Science, presenting the discovery and novel mechanism of action of MDV3100, the Company's androgen receptor antagonist drug candidate. MDV3100 has completed enrollment in a Phase 1-2...

2009-01-01 08:14:15

Johns Hopkins scientists identify receptor type that makes cancer cells resistant to therapy, more aggressive The hormone deprivation therapy that prostate cancer patients often take gives them only a temporary fix, with tumors usually regaining their hold within a couple of years. Now, researchers at Johns Hopkins have discovered critical differences in the hormone receptors on prostate cancer cells in patients who no longer respond to this therapy. The findings, reported in the Jan. 1 issue...

2008-12-31 16:15:39

Hormone deprivation therapy that prostate cancer patients often take gives them only a temporary fix, but U.S. researchers suggest why. Jun Luo of Johns Hopkins University and colleagues at the University of Washington and Puget Sound VA Medical Center said they have discovered critical differences in the hormone receptors on prostate cancer cells in patients who no longer respond to this therapy. Prostate cancer cells rely on androgens -- male hormones that include testosterone -- to...

2008-10-24 09:00:07

Ariad Pharmaceuticals has reported encouraging preclinical data on the investigational mTOR inhibitor, deforolimus, alone or in combination with the anti-androgen agent, bicalutamide, in models of prostate cancer. This investigational study shows that the combination inhibits the growth of prostate cancer cell lines in various model systems. This data provide the scientific rationale for an ongoing Phase II clinical trial examining the same combination in patients with advanced prostate...

2008-10-23 09:00:38

Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that results from an ongoing Phase II clinical trial of Cougar's investigational drug CB7630 (abiraterone acetate) were presented today at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics." The Symposium is currently taking place in Geneva, Switzerland. The Phase II clinical trial of CB7630 (COU-AA-002) is being conducted at the University of California, San Francisco Comprehensive Cancer Center with...

2008-10-23 09:00:10

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today presented preclinical data on the investigational mTOR inhibitor, deforolimus, alone or in combination with the anti-androgen agent, bicalutamide, in models of prostate cancer. This investigational study shows that the combination inhibits the growth of prostate cancer cell lines in various model systems. The data were presented at the EORTC-NCI-AACR (ENA) symposium on "Molecular Targets and Cancer Therapeutics" held in Geneva, Switzerland this...

2008-10-21 12:00:08

Ariad Pharmaceuticals, a developer of medicines to treat cancer, has announced the initiation of a Phase II clinical trial by Merck & Co to evaluate the safety and efficacy of oral deforolimus, Ariad's investigational mTOR inhibitor, in patients with advanced prostate cancer. In collaboration with Merck, deforolimus is currently being studied in multiple clinical trials, both alone and in combination with other therapies, in patients with several different types of cancer. Under the...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related